Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Concert Pharmaceutic (NQ: CNCE )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Concert Pharmaceutic

< Previous 1 2 3 4 5 Next >
Concert Pharma Aces Second Trial For Patchy Hair Loss Hopeful
Via Benzinga
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss
Via Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. 
Via Benzinga
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
From Concert Pharmaceuticals, Inc.
Via Business Wire
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
From Concert Pharmaceuticals, Inc.
Via Business Wire
74 Biggest Movers From Yesterday
Gainers 
Via Benzinga
53 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Concert Pharmaceuticals Announces Pricing of Public Offering
From Concert Pharmaceuticals, Inc.
Via Business Wire
62 Biggest Movers From Yesterday
Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday. 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping 100 points on Wednesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Mid-Day Market Update: Dow Dips 200 Points; Tonix Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Wednesday. 
Via Benzinga
44 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! Busy traders are already at work this morning as we go over the biggest pre-market stock movers for Wednesday. 
Via InvestorPlace
18 Stocks Moving in Wednesday's Pre-Market Session
Gainers Endo International plc (NASDAQ: ENDP) rose 46.1% to $0.7710 in pre-market trading after gaining over 12% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Concert Pharmaceuticals, Inc.
Via Business Wire
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
Via Benzinga
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
Via Benzinga
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.